29 April 2019 to 4 May 2019
Erice
Europe/Zurich timezone

Contribution List

68 / 68
Prof. John Olivier Prior, Dr Thierry Stora (CERN)
30/04/2019, 09:00
Mr Stephen Ahenkorah (SCK•CEN, Belgian Nuclear Research Centre, Institute for Health, Environment and Safety, Radiochemistry Unit, Mol, Belgium; SCK•CEN, Belgian Nuclear Research Centre, Institute for Health, Environment and Safety, Radiobiology Unit, Mol, Belgium; Radiopharmaceutical Research, Department of Pharmacy and Pharmacology, KU Leuven, Leuven, Belgium.)
30/04/2019, 15:40
Preclinical research and development of new radiopharmaceuticals
Oral

Objectives: Targeted α-radionuclide therapy is a promising cancer therapy that allows targeted irradiation of primary tumour and its metastases. 213Bi-DOTATATE targeting the somatostatin receptor has been reported to delay growth in small and large volume endocrine tumours in mice (1,2). However, DOTA chelator has poor labelling kinetics and radiochemical purity with Bismuth-213. It...

Ms Sophia Pells (University of Manchester (GB), National Physical Laboratory (GB)) , Dr Nick Calvert (The Christie NHS Foundation Trust,) , Thomas Elias Cocolios (KU Leuven - IKS) , Mr Kristof Dockx (KU Leuven (BE)) , Simon Thomas Stegemann (KU Leuven) , Ulli Koester (Institut Laue-Langevin (FR)) , Ben Pietras (University of Manchester) , Mr Emlyn Price (The University of Manchester, The Christie NHS Foundation Trust) , Dr Sean Collins (The National Physical Laboratory) , Dr Ana Denis-Bacelar (The National Physical Laboratory) , Mr Andrew Fenwick (The National Physical Laboratory) , Ms Kelley Ferreira (andrew.fenwick@npl.co.uk) , Dr David Hamilton (The Christie NHS Foundation Trust) , Dr Kerttuli Helariutta (University of Helsinki) , Dr Peter Ivanov (The National Physical Laboratory) , Ellen Helen Ulrika Jakobsson (Helsinki Institute of Physics (FI)) , Karl Johnston (CERN) , Dr John Keightley (The National Physical Laboratory) , Dr Christopher Oldfield (The Christie NHS Foundation Trust, The University of Manchester) , Ms Emma Page (The University of Manchester, The Christie NHS Foundation Trust) , Dr Ben Russell (The National Physical Laboratory) , Juliana Schell (Institut Fur Materialwissenschaft Universität Duisburg-Essen (D) , Dr Jill Tipping (The Christie NHS Foundation Trust) , Mr Ben Webster (The National Physical Laboratory, University of Surrey) , Dr Jill L. Wevrett (The National Physical Laboratory, Royal Surrey County Hospital)
01/05/2019, 10:00
Preclinical research and development of new radiopharmaceuticals
Oral

There has been increasing interest in four radioisotopes of terbium with the potential for use in nuclear medicine: 161Tb emits therapeutic beta and Auger particles; 155Tb emits gamma-rays suited to Single-Photon Emission Computed Tomography (SPECT); 152Tb emits positrons suitable for Positron Emission Tomography (PET); and 149Tb emits alpha particles suitable for therapy. Their identical...

Simon Thomas Stegemann (KU Leuven)
02/05/2019, 18:16